A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have type 2 diabetes mellitus (T2DM)
Participants must be receiving stable dose of long-acting insulin and at least 2 injections of mealtime insulin per day for 90 days
Participants must be taking diabetes medication for 3 months before entering the study
Participants must have stable body weight for the last three months
Participants Must Not:
Participants must not have type 1 diabetes mellitus (T1DM)
Participants must not have received any of the following insulin therapies in the past 90 days- insulin mixtures, inhaled insulin, insulin pump therapy, or regular insulin U-500
Participants must not have received certain nonallowed oral diabetes medication within prior 90 days
Participants must not have had an episode of very low blood glucose level within the last 6 months of starting the study
Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
Participants must not have lost or gained significant weight in the last 3 months
Participants must not have known liver disease
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo